(EVH) Evolent Health, Inc. Porters Five Forces Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(EVH) Evolent Health, Inc. Complete Analysis Pack
Don't Miss the Bigger Picture
This Evolent Health, Inc. Porter's Five Forces Analysis helps you understand the competitive pressures shaping the company’s industry, including rivalry, buyer power, supplier power, substitutes, and new entrants. This page already shows a real preview of the analysis, so you can review the content before buying. Purchase the full version for the complete ready-to-use report.
Suppliers Bargaining Power
Specialized clinical talent
Physicians, nurses, and oncology and cardiology specialists are key inputs for Evolent Health, Inc., and scarce labor gives them wage leverage. The U.S. Bureau of Labor Statistics projects 6% RN growth and 3% physician growth through 2033, with about 194,500 RN openings a year, so hiring pressure can lift costs and slow scaling. Evolent Health, Inc. has to lean on training, workflow design, and tech to cut that dependence.
Data and interoperability vendors
Evolent Health, Inc. depends on claims data, clinical feeds, analytics tools, and system links to run Identifi, so data and interoperability vendors can hold real bargaining power. Switching a core data or healthcare IT provider can be costly and disruptive, especially if feeds break or prior authorization and care management workflows slow down. Any vendor concentration or renewal pressure can lift input costs and squeeze margins.
Cloud and software infrastructure
Cloud hosting, cybersecurity, workflow software, and enterprise systems are core to Evolent Health, Inc.’s daily work, so supplier switching is limited. The top three cloud providers controlled about 63% of global infrastructure spend in 2024, which gives large vendors pricing power even as they benefit from scale. Because U.S. healthcare breach costs averaged $10.93 million in 2024, Evolent Health, Inc. cannot risk outages or weak security, so supplier power stays moderate, not low.
Provider network dependencies
Evolent Health, Inc. faces moderate supplier power because its value-based care models rely on hospitals, physician groups, and specialty providers joining its pathways. In markets where 2 or 3 large systems dominate local care, those providers can push back on workflow rules or pricing. If a network is hard to replace, it can shape service design and economics, but proof of total cost of care savings should reduce that leverage over time.
- Dependent on provider participation
- Local systems can resist requirements
- Switching costs raise supplier power
- Savings proof weakens pressure
Regulatory and compliance specialists
Regulatory and compliance specialists have strong supplier power for Evolent Health, Inc. because healthcare rules, payer contracts, coding standards, and privacy duties need niche legal and audit skill. One HIPAA breach can cost millions, and Medicare/Medicaid coding or reporting errors can trigger denied claims or contract loss, so Evolent must keep paying for outside expertise. As regulation gets more complex, these suppliers can charge more and Evolent must keep spending on governance and reporting.
- Specialized expertise is hard to replace.
- Errors can mean penalties or lost contracts.
- Complex rules raise supplier pricing power.
- Governance spend stays structurally high.
Evolent Faces High Supplier Power from Scarce Clinicians and Cloud Giants
Evolent Health, Inc. faces moderate supplier power because scarce clinicians and niche data, cloud, and compliance vendors can raise costs. RN demand is projected to grow 6% and physician demand 3% through 2033, while the top three cloud providers held about 63% of global infrastructure spend in 2024, so switching is hard and pricing power stays real.
| Supplier | Power | Key number |
|---|---|---|
| Clinicians | High | 6% RN growth |
| Cloud | High | 63% share |
What is included in the product
Detailed Word Document
Assesses Evolent Health, Inc.’s competitive pressures from rivals, buyers, suppliers, substitutes, and new entrants.
Customizable Excel Spreadsheet
A clear Porter's Five Forces snapshot for Evolent Health, Inc. that quickly reveals market pressure and strategic risks.
Reference Sources
Provides a credible source trail for Evolent Health, Inc., making key assumptions easier to verify, defend, and act on.
Customers Bargaining Power
Large health plan buyers
Evolent Health, Inc. sells mainly to large health plans like UnitedHealth Group, which reported over $400 billion in 2024 revenue, and Elevance Health, at about $175 billion. These buyers are sophisticated, can compare vendors fast, and often demand proof of outcomes plus pricing or performance guarantees. Because contracts are large, losing one account can hit revenue hard, so customer bargaining power stays high.
Provider clients can switch cautiously
Health systems and physician groups can switch if Evolent Health, Inc. misses measurable ROI, and renewals often hinge on hard proof of clinical and financial gains. Even though switching is operationally messy, buyers still press for better terms because they can compare vendors through formal RFPs and long review cycles.
Customer power stays high at renewal because CFOs and clinicians care about workflow fit, physician adoption, and outcomes, not just contract language. Evolent Health, Inc. must show lower cost trends, better quality scores, and stable provider use to protect retention.
Outcome-based purchasing pressure
Evolent Health, Inc. faces rising customer pressure to tie fees to savings, quality, and lower utilization, not just cost-plus pricing. That shifts more downside risk to Evolent and pushes buyers to demand shared savings, downside protection, and service-level guarantees. As healthcare analytics and reporting get sharper, this outcome-based pricing pressure keeps getting stronger.
Concentrated buyer groups
Evolent Health, Inc. faces strong buyer power because a few large national and regional payers can drive a meaningful share of revenue. In FY2025, Evolent still depended on retaining and expanding these accounts, so each client has real leverage in pricing and contract terms.
These buyers can compare Evolent with internal teams and other outsourced care-management firms, which pushes down margins. The result is a retention-led model: keeping contracts and growing within each payer matters more than winning lots of small customers.
- Few buyers, high account value
- More pricing pressure
- Easy benchmarking against rivals
- Retention and expansion are key
High compliance and service expectations
Evolent Health, Inc. faces strong buyer power because customers expect HIPAA-grade data protection, care coordination, and CMS-ready reporting, all while pushing for custom integrations at low extra cost. That pressure is high in 2025 because healthcare buyers manage millions of member records and cannot afford compliance lapses, so service quality matters as much as price. Still, once Evolent is embedded, switching gets hard and expensive.
- High compliance needs raise buyer demands
- Custom work often gets bundled in
- Implementation creates switching friction
- Buyer power stays strong overall
Evolent Faces Strong Buyer Power as Large Payers Push Harder on Terms
Evolent Health, Inc. faces strong customer power because a few large payer clients can shift a big share of revenue and push hard on price, fees, and guarantees. In FY2025, buyers kept leverage by tying renewals to measurable ROI, quality scores, and lower utilization. Switching is costly, but formal RFPs and outcome-based contracts still let customers press for better terms.
| Metric | Signal |
|---|---|
| FY2025 | High buyer leverage |
| Account base | Few large buyers |
| Contract terms | Outcome-linked pricing |
Full Version Awaits
Evolent Health, Inc. Porter's Five Forces Analysis
This preview shows the exact Evolent Health, Inc. Porter's Five Forces Analysis you’ll receive after purchase—no edits, no placeholders, and no surprises. The document is fully formatted and ready to use the moment you buy it. What you’re viewing now is the same final file delivered to you instantly after payment.
Rivalry Among Competitors
Many healthcare services competitors
Evolent Health, Inc. faces intense rivalry from large health services firms, niche clinical platforms, consultants, and payer-owned tools. The market is fragmented, so pricing stays tight and differentiation is hard. Evolent’s 2024 revenue was about $1.8 billion, showing it plays in a crowded, scale-driven space.
Outcome differentiation is hard
Winning here depends on showing lower total cost of care, better quality, and stronger physician engagement. Evolent Health’s Identifi platform helps, but rivals still market similar claims, so buyers focus on hard results, not features. Evolent reported about $2.5 billion of 2024 revenue, yet when outcomes are hard to verify, competition still shifts to price and existing relationships.
Long sales cycles and account battles
Healthcare enterprise deals run on long diligence, multi-party buy-in, and tough contract talks, so every Evolent Health account becomes a bake-off. That raises rivalry in renewals too, because rivals can attack with lower pricing or faster go-live claims. Long cycles do not soften competition; they make each win worth more, so sales teams fight harder for each contract.
Technology and AI escalation
Competitors are pouring money into analytics, automation, and AI-led care management, so the bar for product depth and operating speed keeps rising. In this market, Evolent Health, Inc. cannot rely on service mix alone; it has to keep upgrading its tech stack or risk being treated like a commodity.
As digital tools become standard, rivalry shifts from features to proof: cleaner data, better workflow accuracy, and measurable clinical outcomes. That means the winners will be the firms that can show lower avoidable spend, faster care routing, and stronger performance on quality metrics.
- AI raises product and cost pressure.
- Data quality now drives differentiation.
- Clinical results matter more than features.
Specialty focus competition
Oncology and cardiology stay hot because they sit in the highest-cost parts of care, so even small savings matter. That pulls in rivals with deep specialty teams, claims data, and payer ties, making rivalry more direct than broad-care markets. Evolent Health, Inc. has to win on specialty know-how, tight workflows, and proof it can lower total cost of care.
- High-cost care attracts focused rivals
- Clinical depth and payer links matter
- Proof of savings is the key defense
High Rivalry, Low Pricing Power: Evolent Must Prove Real Outcomes
Competitive rivalry is high for Evolent Health, Inc. because the market is crowded, deals are hard to win, and buyers compare proof, not promises. Specialty care like oncology and cardiology draws rivals with payer ties, so price pressure stays strong and differentiation depends on measured savings and outcomes.
| Signal | Effect |
|---|---|
| Crowded market | Weak pricing power |
| Outcome proof | Key edge |
Substitutes Threaten
Internal payer capabilities
Internal payer teams are a strong substitute for Evolent Health, Inc. because health plans can build care management, analytics, and utilization management in-house instead of outsourcing. This appeals to buyers that want tighter control, better data access, and less vendor dependence. Large payers with mature data systems can replicate much of the model, so this is a significant threat.
Generalist consulting firms
Generalist consulting firms are a real substitute for Evolent Health, Inc. on strategy, transformation, and operating redesign work, especially when buyers only need short-term help. Accenture reported FY2024 revenue of $64.9 billion, showing how large these substitute providers are. Still, they usually lack Evolent Health, Inc.'s ongoing clinical operations depth, so the threat is highest for non-core or temporary needs.
Point solutions and software tools
Point solutions are a real substitute: buyers can stitch together analytics, care coordination, prior authorization, and patient engagement tools instead of buying one integrated platform. That fits budget pressure and modular procurement, but fragmented tools often miss the population-health lift an end-to-end model can deliver. In 2025, Evolent Health still faces this risk as payers and providers keep trimming admin spend and favoring smaller, easier-to-swap contracts.
Provider-owned management teams
Provider-owned management teams are a real substitute for Evolent Health, Inc. Large systems can build their own value-based care, specialty management, and patient navigation teams, which keeps incentives in-house and cuts partner fees. The risk is highest for scale players with the capital to fund tech, staff, and analytics. Evolent has to prove faster care coordination and better unit economics.
- Large providers can self-build.
- Scale lowers outside-partner need.
- Internal teams align incentives.
- Evolent must win on speed and cost.
Fee-for-service inertia
Fee-for-service inertia is a real substitute risk for Evolent Health, Inc.: if health systems delay value-based care, they keep using older workflows and reduce near-term demand for Evolent Health, Inc.'s services. CMS says 66.4 million people were in Medicare Advantage in 2025, but adoption still varies a lot by payer and provider, so the shift is not even. That keeps substitution at a medium level.
- Delays cut immediate demand
- Adoption is still uneven
- Market shift favors value-based care
High Substitute Pressure on Evolent Health
Threat of substitutes is high for Evolent Health, Inc. Health plans can self-build care management, analytics, and utilization tools, while large provider systems can keep value-based care work in-house. Point solutions and consulting firms also pull spend away, especially when buyers want lower cost and faster switching.
| Substitute | Why it wins |
|---|---|
| Internal teams | Control, data, lower fees |
| Point tools | Modular, easier to swap |
| Consulting | Short-term help |
Entrants Threaten
Regulatory and compliance barriers
Healthcare new entrants face hard gates: HIPAA privacy rules, complex billing, payer contracting, and clinical governance all need mature controls before major payers or providers will sign. Building that stack takes time and cash, and one compliance miss can trigger audits, fines, or contract loss. For Evolent Health, Inc., regulation is a real barrier to entry.
Data scale and integration hurdles
Evolent Health, Inc. faces a strong barrier because its model depends on joining claims, clinical, and ops data fast and clean. New entrants would need the same large datasets, plus the tools and staff to normalize them, which is costly and slow. The harder part is not software alone; it is years of payer and provider implementation know-how and trusted relationships.
Trust and reputation requirements
Healthcare buyers won’t risk critical workflows or patient data with an unproven vendor, so trust is a real entry barrier. Evolent Health’s long record in complex specialty care and reference-driven sales helps it win against new entrants, while startups without proven outcomes face longer sales cycles and tougher security reviews.
Capital and sales-cycle intensity
Capital and sales-cycle intensity keeps new entrants out of Evolent Health, Inc.’s market. Building a payer-facing platform needs heavy spend on technology, clinical talent, and compliance before the first big contract closes, and enterprise sales can stretch for months, so small startups burn cash fast. That makes fast scale hard and pushes many would-be entrants aside.
- High upfront tech and compliance spend
- Long enterprise sales cycles delay revenue
- Cash burn hurts small startups
- Capital intensity deters new entrants
AI lowers some barriers
AI and cloud tools cut the cost of building analytics and workflow software, so smaller firms can target narrow payer, care-management, or utilization-review niches faster. That raises the threat to Evolent Health, Inc., but healthcare is still hard: payer contracts, clinical depth, HIPAA controls, and regulatory readiness take time and capital.
So the threat is real, yet moderated by operating complexity. A new entrant may copy a feature set, but it still has to win trust, integrate with payer systems, and prove outcomes at scale.
- AI lowers build costs and speeds launch.
- Niche attacks are easier now.
- Trust, compliance, and payer ties still block entry.
Moderate Entry Threat: Trust and Compliance Still Protect Evolent
Threat of new entrants is moderate. AI and cloud tools lower startup costs, but Evolent Health, Inc. still benefits from deep payer ties, HIPAA-grade controls, and hard-won implementation know-how.
New vendors must win trust, pass security reviews, and prove outcomes before large contracts, so sales cycles stay long and cash burn stays high.
| Barrier | Effect |
|---|---|
| Compliance | High |
| Payer trust | High |
| Capital need | High |
| AI tools | Raise threat |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.